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Molecular imaging of inflammation
and intraplaque vasa vasorum: A step forward
to identification of vulnerable plaques?
Gerrit L. ten Kate, MD,a,b Eric J. G. Sijbrands, MD, PhD,a Roelf Valkema, MD,
PhD,c Folkert J. ten Cate, MD, PhD,b Steven B. Feinstein, MD,d
Antonius F. W. van der Steen, PhD,e Mat J. A. P. Daemen, MD, PhD,f
and Arend F. L. Schinkel, MD, PhDa,b
Current developments in cardiovascular biology and imaging enable the noninvasive molecular
evaluation of atherosclerotic vascular disease. Intraplaque neovascularization sprouting from
the adventitial vasa vasorum has been identified as an independent predictor of intraplaque
hemorrhage and plaque rupture. These intraplaque vasa vasorum result from angiogenesis,
most likely under influence of hypoxic and inflammatory stimuli. Several molecular imaging
techniques are currently available. Most experience has been obtained with molecular imaging
using positron emission tomography and single photon emission computed tomography.
Recently, the development of targeted contrast agents has allowed molecular imaging with
magnetic resonance imaging, ultrasound and computed tomography. The present review dis-
cusses the use of these molecular imaging techniques to identify inflammation and intraplaque
vasa vasorum to identify vulnerable atherosclerotic plaques at risk of rupture and thrombosis.
The available literature on molecular imaging techniques and molecular targets associated with
inflammation and angiogenesis is discussed, and the clinical applications of molecular cardio-
vascular imaging and the use of molecular techniques for local drug delivery are addressed.
Key Words: Atherosclerosis Æ angiogenesis Æ inflammation Æ molecular imaging Æ vasa
vasorum Æ vulnerable atherosclerotic plaque
INTRODUCTION
The combination of cardiovascular and molecular
imaging is rapidly evolving. Current developments in
cardiovascular biology and imaging provide noninvasive
molecular evaluation of atherosclerotic vascular disease,
aiding in the detection of vulnerable plaques, at risk of
rupture and subsequent thrombosis.1,2 Essential to the
successful development of molecular imaging is the
search for a safe, noninvasive imaging technique capa-
ble of early detection of the key pathological processes
of cardiovascular disease, identifying vulnerable plaques
and thus patients at an increased risk of cardiovascular
events.3
A number of pathophysiological mechanisms are
thought to be involved in the progression of an athero-
sclerotic lesion into a vulnerable plaque.4 Intraplaque
neovascularization of the vasa vasorum has gained
interest as a preceding or concomitant factor in the
development, progression, and instability of atheroscle-
rotic plaques.5-7 The intraplaque vasa vasorum are
microvessels that sprout from the adventitial vasa
vasorum, most likely under influence of hypoxic and
inflammatory stimuli.8-12 The presence of intraplaque
vasa vasorum has been identified as an independent
predictor of intraplaque hemorrhage and plaque
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rupture.13,14 The intraplaque vasa vasorum are therefore
increasingly investigated as a marker for the noninvasive
identification of vulnerable plaques.
In the present review, the noninvasive molecular
imaging of vasa vasorum neovascularization in the
atherosclerotic plaque is discussed. First, an overview of
the characteristics of vulnerable plaques and the role of
inflammation and angiogenesis in vasa vasorum neo-
vascularization is provided. Subsequently, the available
literature on molecular imaging techniques and molec-
ular targets associated with inflammation and angio-
genesis is discussed. Finally, local drug delivery and the
clinical application of molecular imaging in early
detection of cardiovascular disease, evaluation of
treatment effects, and use in drug development are
addressed.
PATHOPHYSIOLOGY OF THE VULNERABLE
PLAQUE
Traditionally, the burden of atherosclerotic disease
was estimated from the percentage of stenosis detected
by angiography. However, it has become apparent that
plaque rupture and consequent cardiovascular events are
dependent on the plaque composition rather than ste-
nosis. Analyses of culprit lesions demonstrated that
plaques vulnerable to rupture are characterized by active
inflammation, a large lipid core with a thin fibrous
cap, positive remodeling, intraplaque hemorrhage, and
intraplaque neovascularization of the vasa vasorum.4
Inflammation
Inflammation is one of the hallmarks of plaque
vulnerability. Macrophages are the most prevalent
inflammatory cell in the atherosclerotic plaque and play
a major role in the pathophysiology of plaque vulnera-
bility.4,15,16 Macrophages secrete proteolytic enzymes,
which degrade the extracellular matrix weakening the
fibrotic cap structure and ultimately leading to plaque
rupture. In addition, macrophages may secrete proangio-
genic factors that stimulate the formation of vasa vaso-
rum in atherosclerotic lesions.6,9,17 The vasa vasorum
may serve as an important port of entry for additional
inflammatory cells into the plaque.18,19
Vasa Vasorum Neovascularization
The vasa vasorum are functional end arteries,
physiologically present in the adventitia of large arteries
(vessels with a wall thickness [ 0.5 mm). The vasa
vasorum provide nutrients to parts of the vessel wall that
are too distant from the lumen for diffusion.6,12,20
Interruption of the adventitial vasa vasorum results in
media necrosis, showing they are critical for the nour-
ishment of the media.21-23
In the pathology of atherosclerosis dual, apparently
contradictory roles for the vasa vasorum have been
proposed.24 Vessel wall areas with low adventitial vasa
vasorum density have been identified as preferred
locations for the initiation of plaque formation, while the
progression to advanced, symptomatic plaques is
associated with a high intraplaque vasa vasorum
density.10,11,25,26
The vasa vasorum are unevenly distributed along
the vessel wall. It has been hypothesized that areas of
low vasa vasorum density have less efflux of lipopro-
teins and are prone to inflammation. The influx of
monocytes and subsequent differentiation into macro-
phages increase the metabolic demand in the vessel wall,
while the supporting microvasculature may be insuffi-
cient. A relative hypoxic state and increased oxidative
stress may occur, which may be the trigger for the for-
mation of an atherosclerotic plaque. This hypothesis has
been supported by the presence of hypoxic and inflam-
matory factors as hypoxia-inducible factor-1a (HIF-1a),
nuclear transcription factor-kappa B, tumor necrosis
factor-a and interleukin-6, and an increased number of
superoxide anions in regions with low vasa vasorum
density.11,25,27-29
The increased density of vasa vasorum in advanced
and symptomatic plaques is the result of microvessels
sprouting from the existing adventitial vasa vasorum
network by the process of angiogenesis. The initiation of
angiogenesis is thought to be a physiological response to
the inflammatory and hypoxic state of the vessel wall.
The intraplaque vasa vasorum are formed to meet the
increased metabolic demands of the developing athero-
sclerotic plaque. However, due to their poor structural
integrity the intraplaque vasa vasorum may serve a
pathologic role.10,18,25,26,30 They are immature, thin-
walled vessels with increased size and even absence of
the endothelial gap junctions (Figure 1). This may result
in the extravasation of lipids, inflammatory cells and red
blood cells and risks the collapse of the microvessels,
contributing to progression into more advanced plaques.
In humans over 80% of the intraplaque vasa vasorum are
thin-walled and prone to leakage and rupture.31,32
Plaques with a high vasa vasorum density are conse-
quently at an increased risk of intraplaque hemorrhage
and plaque rupture.7,25
Whether the initiation of angiogenesis is an early or
late process in the formation of the atherosclerotic
plaques is still debated. Moreover, the key factors ini-
tiating angiogenesis in the atherosclerotic plaque are still
largely unknown.25,33 An increase in vasa vasorum
density has been shown to precede intimal thickening
and even endothelial dysfunction. The latter is
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traditionally thought of as one of the earliest changes in
plaque development.34-36 Further studies are needed to
elucidate the temporal relation and molecular regulation
of angiogenesis in plaque formation.
MOLECULAR IMAGING
The recent years have seen a flight in both non-
invasive (Table 1) and catheter-based molecular car-
diovascular imaging techniques.37,38 Many of the
developments have come from the field of cancer
imaging, where molecular imaging by positron emission
tomography (PET) and single photon emission
computed tomography (SPECT) is readily used in
clinical practice. Magnetic resonance imaging (MRI),
ultrasound, and computed tomography (CT) are used in
clinical practice for the visualization of anatomical
structures, without necessarily visualizing biological
processes. The development of targeted contrast agents
has created a possibility for molecular imaging with
these imaging techniques.
Molecular contrast agents generally consist of a
ligand and a contrast element. The ligand is a molecule,
for example an antibody, antibody fragment, peptide, or
oligosaccharide, with a specific binding capacity to a
molecular target. Its function is to retain the contrast
element at the site of interest. The attached contrast
element is specific to the imaging modality used, for
example a radionuclide tracer for PET and SPECT,
iodine for CT, gadolinium for MRI, or microbubbles for
ultrasound. The contrast element can either be attached
directly to the ligand, or via a carrier vehicle, such as a
micelle, nanoparticle, or microbubble. In practice,
multiple functions can be incorporated in one element.39
Both PET and SPECT imaging are used in
conjunction with an intravenously administrated radio-
nuclide tracer. To create an image PET and SPECT are
dependent on the physical signal, either a positron or a
photon, emitted by the tracer. This results in a high
sensitivity for the detection of radionuclide tracers. PET
and SPECT are able to accurately detect the tracer in
very low concentrations (\pg/mL).40 However, these
imaging modalities lack anatomical detail and resolu-
tion, with PET reaching a maximum resolution of
approximately 5 mm (two to three times better than
SPECT).38 The use of radionuclide tracers is associated
with ionizing radiation, and this potentially limits the
clinical application. Much effort has been directed
toward reducing the radiation dose and the effective
dose equivalent (approximately 370 MBq, 6.23 mSv)
and organ doses are now comparable or lower than the
radiation dose used in CT examinations, depending on
the CT acquisition protocol.41 With modern equipment
even lower activities of the tracer are required and a safe
total radiation dose can be achieved.
For molecular imaging, MRI can be used in con-
junction with either gadolinium or super paramagnetic
iron oxide compounds (SPIO) that influence the mag-
netic resonance signal, resulting in an increase in T1 or
a decrease in T2 signal, respectively.42 The predomi-
nantly used clinical MRI systems use a 1.5-T field
strength and are capable of reaching submillimeter
resolutions. MRI avoids the use of ionizing radiation.
However, gadolinium has been associated with neph-
rogenic systemic fibrosis in patients with reduced renal
function.43,44
Ultrasound molecular contrast agents consist of
microbubbles (1-5 lm diameter) stabilized by a lipid or
Figure 1. Schematic cross section of an atherosclerotic vessel
with a large plaque, lipid core, and intraplaque vasa vasorum
sprouting from the adventitial vasa vasorum network. Panel A
shows the normal structure of the vasa vasorum with tight gap
junctions. Panel B shows newly formed vasa vasorum with
increased endothelial gap junctions, pericyte loss and expres-
sion of cellular adhesion molecules, the extravasation of
erythrocytes1 and their consequent destruction, the adhesion
and extravasation of monocytes2 and their subsequent trans-
formation to macrophages and resultant foam cells and the
direct extravasation of lipids.3 These factors cause growth of
the lipid core of the atherosclerotic plaque.
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protein shell. The microbubbles are an obligatory
intravascular contrast agent, and the presence of mi-
crobubbles in an atherosclerotic plaque indicates the
presence of intraplaque vasa vasorum. Ultrasound
uniquely combines a submillimeter resolution and the
capability to detect individual microbubbles, making
contrast-enhanced ultrasound capable of identifying
individual vasa vasorum in the vessel wall. However,
the limited penetration depth restricts ultrasound to
the investigation of the superficial vasculature.45-47
Ultrasound contrast agents have been used in echocar-
diography for decades and have been proven safe in
large multicenter studies.48
Recently, the first molecular contrast agents have
been developed for CT.40 Molecular CT imaging uses
iodinated nanoparticles that increase the X-ray absorp-
tion at the targeted location. The high speed whole body
scanning capability of multislice CT allows accurate
visualization of atherosclerotic plaques in the coronary
arteries.40,49 The use of multislice CT for molecular
imaging of the coronary arteries has not yet been
investigated. The use of ionizing radiation potentially
limits the use of CT, though the radiation dose in car-
diovascular CT has substantially been reduced in recent
years by the introduction of prospective ECG gating.50
The use of iodine contrast agents CT risks the devel-
opment of a contrast-induced nephropathy, limiting its
use in patients with decreased renal function.51
MOLECULAR TARGETS
The search for a safe, noninvasive imaging tech-
nique capable of early detection of atherosclerosis and
risk stratification of patients with cardiovascular disease
has resulted in the identification of various target-ligand
combinations that are associated with plaque vulnera-
bility. Angiogenesis and inflammation are closely
related pathophysiological processes which are involved
in both early plaque development and plaque vulnera-
bility in patients with more advanced atherosclerosis.
Tables 2 and 3 provide an overview of the molecular
targets investigated for the identification of inflamma-
tory and angiogenic processes respectively.
INFLAMMATION-RELATED MOLECULAR
TARGETS
Macrophages
Inflamed plaques show an increased metabolism as
a result of the increase in inflammatory cells, predomi-
nantly macrophages. The increased metabolism can
be visualized by 18F-fluorodeoxyglucose (FDG) PET
(Figure 2). FDG is a radionuclide-labeled glucoseT
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analogue taken up by all cells in proportion to their
metabolic activity, especially glycolysis and is thus able
to identify locations with high metabolism or dispro-
portionate glucose use. The in vivo visualization and
quantification of plaque inflammation by FDG-PET
have been shown both in animals52-55 and humans.56-60
Davies et al investigated 12 patients who had all
suffered a recent transient ischemic attack. Of the 12
stenotic lesions identified as the culprit lesion on con-
ventional angiography, 7 showed a high FDG uptake. In
the remaining three patients, three had a high FDG
uptake in a nonstenotic lesion in the vascular territory
compatible with the patients’ symptoms. In these
patients, the culprit lesion could not have been identified
with angiography. FDG-PET had the potential to iden-
tify inflamed nonstenotic atherosclerotic lesions;
however, no histology was obtained to confirm the
findings.61
FDG-PET has also been used to evaluate treatment
effects. Tahara et al randomized 43 patients undergoing
FDG-PET for cancer screening to either statin treatment
or dietary management only. After 3 months of treat-
ment, FDG uptake in the atherosclerotic plaque had
significantly decreased in the statin group, while no
change was observed in the diet group.62 This intriguing
observation suggests that FDG-PET has the potential to
evaluate the effect of treatment on plaque inflammation.
Other contrast agents have been developed to
identify macrophages in an atherosclerotic plaque.
Rogers et al showed that in vitro SPIO compounds are
nonspecifically taken up by macrophages under influ-
ence of cytokines, serum components and statin
treatment.63 A number of in vivo MRI studies have
shown that SPIO compounds localize macrophages in
animal64-66 and human67-71 atherosclerotic plaques
(Figure 3). Hyafil et al used iodinated nanoparticles and
showed a nonspecific uptake in macrophages in vitro.
Subsequently, an in vivo study in 12 rabbits with
induced atherosclerotic plaques showed that macro-
phage rich tissue could be detected by CT (Figure 4).49
Lipinski et al investigated gadolinium micelles and
immuno-micelles targeted at the macrophage scavenger
receptor in an ex vivo MRI study. Gadolinium micelles
were nonspecifically taken up by macrophages. Notably,
the specific up take of the immuno-micelles was sig-
nificantly higher. These promising results suggest that
immuno-micelles can be used to improve the detection
of macrophages but of course they need to be repro-
duced in vivo.72
Cellular Adhesion Molecules
Endothelial expression of adhesion molecules has
been identified as one of the earliest changes in the
formation of atherosclerotic plaques.15 Vascular cell
adhesion molecule-1 (VCAM-1) and intercellular adhe-
sion molecule-1 (ICAM-1) are involved in the adhesion
and subsequent extravasation of inflammatory cells.
Both VCAM-1 and ICAM-1 are expressed by the
endothelium overlying the atherosclerotic plaque.
However, the most dominant expression of VCAM-1
and ICAM-1 is found at the adventitial site of the plaque
and correlates with sites of vasa vasorum neovasculari-
zation, vascular permeability and high inflammatory cell
density.18,30 VCAM-1 and ICAM-1 targeted contrast
agents have been developed for ultrasound and MRI.
Kaufmann et al showed that VCAM-1-targeted
microbubbles attach to activated murine endothelial
cells in vitro, even under pulsatile high shear stress
conditions.73 Subsequent in vivo experiments showed
ultrasound signal enhancement in the aortic plaques of
apoE deficient mice within 10 min after contrast injec-
tion. VCAM-1 expression was confirmed with
histology.73 In a similar way, ICAM-1-targeted micro-
bubbles were shown to specifically bind to endothelial
cells expressing ICAM-1 in vitro.74 Demos et al
investigated the attachment of ICAM-1-targeted micro-
bubbles to atherosclerotic lesions induced in the femoral
and carotid arteries of Yucatan miniswines.75 They
Figure 2. Transaxial images of FDG-PET (left), CT (middle),
and co-registration of PET and CT (right) showing FDG
uptakes in the carotid arterial plaques (arrowheads) of two
patients. Reproduced with permission from Elsevier.62
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found that ICAM-1-targeted microbubbles attached to
the early stages of atherosclerotic plaque development
(Figure 5), thus possibly identifying early stages of
atherosclerotic vascular disease.75
VCAM-1-targeted gadolinium and SPIO com-
pounds have been investigated in atherosclerotic apoE
knockout mice and successfully identified VCAM-1
expressing endothelial cells in vivo.76,77 In addition,
mice treated with statin therapy showed reduced contrast
effect on MRI and reduced expression of VCAM-1 on
histology.77 Ex vivo human carotid specimens con-
firmed that the VCAM-1-targeted contrast agents
co-localized with VCAM-1 expressing endothelial cells,
showing the feasibility of VCAM-1 imaging.77 ICAM-1-
targeted gadolinium liposomes have been investigated in
mice with autoimmune encephalitis, but not yet in an
atherosclerotic animal model.78
Selectins
Selectins are a group of pro-inflammatory endothe-
lial cell adhesion molecules. E-selectin is up-regulated in
proliferating endothelial cells and has been identified
in angiogenic endothelial cells in tumor tissue.79-81
P-selectin is expressed both due to inflammation and
ischemia-reperfusion damage.79,82
Kang et al developed an e-selectin targeted SPIO
compound and showed in vitro binding to human
endothelial cells and consequently a clear T2 signal
decrease on MRI, demonstrating the feasibility of
e-selectin targeted molecular imaging.83,84 In vivo
e-selectin targeted MRI contrast agents have been used
to identify inflammation in hepatic and muscle tissue of
mice.85,86 However, e-selectin targeted contrast has not
yet been used for in vivo imaging of atherosclerotic
plaques.
McAteer et al showed that p-selectin targeted SPIO
compounds bind to atherosclerotic endothelial cells in
vitro.87 Additionally, McAteer et al demonstrated the
added value of dual-targeted molecular imaging, using
a SPIO compound targeted to both VCAM-1 and
p-selectin in apoE knockout mice. Compared to sepa-
rate VCAM-1 or p-selectin targeted compounds the
Figure 3. Axial 2D gradient-echo MRI of a patient. Pre- (A)
and postcontrast (B) images display the level of the aorta. On the
precontrast image, the aortic wall is homogeneously hyper-
intense (A, arrowhead). Following SPIO administration, a
pronounced signal loss of an area extending from the inner to the
outer surface of the aortic wall can be seen (B, arrowhead). This
vessel segment was considered positive. Note, however, that
there is also a low-intensity ring at the interface between the
aortic wall and lumen on the postcontrast image (B, long arrow).
It is not possible to precisely determine whether the ring is truly
confined to the aortic wall or to the lumen. This appearance is
defined as a ring phenomenon, which is also seen in other
vessels, such as the inferior vena cava (B, small arrowheads).
Reproduced with permission from John Wiley & Sons.67
Figure 4. Axial views of the same atherosclerotic plaque
(white arrowheads) in the aorta of a rabbit, obtained by CT
before (A), during (B) and 2 h after the injection of an iodine
nanoparticle contrast agent (C) or a conventional iodine
contrast agent (D). Adapted with permission from Macmillan
Publishers Ltd.49
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dual-targeted compound showed a significantly
improved endothelial binding capacity on ex vivo
MRI.87
Matrix Metalloproteinase
Matrix metalloproteinases (MMP) are a group of
extracellular matrix degrading enzymes predominantly
excreted by macrophages. MMPs are associated with
angiogenesis, the progression of atherosclerotic plaques
and fibrous cap rupture.88 Lancelot et al showed that
gadolinium immuno-micelles targeted at MMPs were
capable of increasing the MRI signal both in vitro and in
vivo. In addition, the ex vivo use of immuno-micelles
facilitated discrimination between MMP-rich and MMP-
poor plaques.89 Ohshima et al investigated the ability
of SPECT in conjunction with a 99mTc-labeled broad
spectrum MMP inhibitor to identify MMP activity in
vivo. There was a significant correlation between the
tracer uptake and the areas positively stained for mac-
rophages, MMP-2 and MMP-9 on histology.90
Summary
The use of small molecule contrast agents, such as
FDG and SPIO, allows for the evaluation of plaque
inflammation due to their ability to pass the endothelial
layer into the plaque and their subsequent uptake by
macrophages. The visualization of cellular adhesion
molecules and selectins may identify plaques actively
recruiting monocytes. The co-localization of cellular
adhesion molecules and selectins with vasa vasorum on
histology might indicate an important additional role for
adhesion molecules in the angiogenic process. Dual-
targeted contrast agents may be used to identify low
levels of expression of adhesion molecules and selectins,
though this might also result in loss of specificity. The
identification of MMP activity could be a technique to
identify atherosclerotic plaques with activated macro-
phages and active remodeling of the extracellular
matrix.
ANGIOGENESIS-ASSOCIATED MOLECULAR
TARGETS
Integrin avb3
Integrins are a large family of cell surface receptors
expressed by several cell types. Integrins play a role in
cell adhesion, migration, and differentiation and are
present both in normal and the atherosclerotic vessel
walls. Integrin avb3 is involved in the migration of
endothelial cells across the basement membrane during
angiogenesis. The expression of integrin avb3 has been
shown to be a marker for angiogenic activity in the
adventitial and intraplaque vasa vasorum.91-94
Integrin avb3-targeted gadolinium contrast has been
investigated in a number of atherosclerotic animal
models. In vivo MRI using an integrin avb3-targeted
gadolinium contrast agent showed a significant increase
in the MRI signal in the atherosclerotic vessel wall.
Expression of integrin avb3, proliferation of angiogenic
vessels and neointima formation was confirmed by his-
tology.95,96 Integrin-targeted contrast agents have also
Figure 5. Transcutaneous ultrasound images of the athero-
sclerotic left carotid artery of a Yucatan miniswine. After
injection of saline (A). After injection of nontargeted micro-
bubbles (B) (arrows point to microbubbles within the lumen).
After injection of ICAM-1 targeted microbubbles (C) (arrows
point to microbubbles attached to the atherosclerotic plaque).
Reproduced with permission from Elsevier.75
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been developed for PET,97 SPECT,98-100 and ultra-
sound.101-103 These contrast agents have not yet been
investigated in an animal model of atherosclerosis.
Fibronectin Extra-Domain B
The fibronectin molecule exists in a number of
polymorphic forms resulting from alternative splicing.
The extra-domain B (ED-B) isoform of fibronectin is not
present in normal adult tissue, but is part of a temporary
extracellular matrix formed during tissue remodeling. The
ED-B fibronectin accumulates around the neovasculature
during angiogenesis and does not accumulate around
mature vessels, making the ED-B fibronectin a marker for
angiogenesis.104 Immunohistochemical analysis demon-
strated an increased expression of fibronectin around the
vasa vasorum in both mice and human plaques.105
ED-B fibronectin-targeted monoclonal antibodies
labeled with radionuclides have been developed to
identify angiogenesis. Matter et al showed that 125I-
labeled monoclonal antibodies against ED-B fibronectin
can be used to specifically target atherosclerotic plaques
in apoE knockout mice and could be identified by
ex vivo autoradiography.105 Although these results are
promising, no in vivo imaging studies have been
performed in an animal model of atherosclerosis.
Nonetheless, in vivo studies have been performed in
tumor models showing the potential for ED-B fibro-
nectin imaging of angiogenesis.106,107
Vascular Endothelial Growth Factor and
Endoglin
Two promising targets for molecular imaging are
the vascular endothelial growth factor (VEGF) receptors
and the transforming growth factor-b binging receptor
endoglin. Both targets are up-regulated by HIF-1a.108
VEGF is the strongest known stimulant of angiogenesis
and is responsible for vascular permeability, while en-
doglin is a cell membrane glycoprotein involved in
vascular development and remodeling. VEGF-receptor2
and endoglin-targeted microbubbles and radionuclides
have been used to study tumor angiogenesis in
mice.103,109-111 Willmann et al investigated the in vivo
binding of dual-targeted microbubbles targeted at the
VEGF-receptor2 and integrin avb3 to angiogenic tumor
vessels in mice. Compared to single-targeted micro-
bubbles, the dual-targeted microbubbles showed a
significantly enhanced binding on ultrasound.103
Summary
Molecular imaging of active angiogenesis is a
promising technique for the evaluation of intraplaque
vasa vasorum sprouting from the adventitial vasa vaso-
rum network. Integrin avb3 and ED-B fibronectin are
potential targets for the identification of intraplaque vasa
vasorum due to their predominant localization around
angiogenic vasculature. It has been shown that integrin
avb3 and ED-B imaging can be performed in vivo ani-
mals. These results have to be reproduced in humans.
The VEGF receptors and endoglin are important
receptors in the angiogenesis pathway. VEGF and en-
doglin-targeted imaging may theoretically be useful for
identifying atherosclerotic plaques with active angio-
genesis. Currently, the number of studies on VEGF and
endoglin is limited and the development of a molecular
imaging approach using these targets clearly needs
further investigation.
DRUG DELIVERY
The nanotechnology used in molecular imaging
opens possibilities for site-specific drug delivery.112,113
The localized delivery of drugs has clear advantages
using lower dosages of more potent drugs and reaching
high concentrations at the target location. The adverse
effects of drugs may be reduced due to decreased con-
centration at nontarget sites. Nanoparticles have been
developed that increase the concentration at the target
location, some of which are already used in clinical
practice.113 However, to date the targeted delivery of
drugs to the atherosclerotic plaque has not yet been
demonstrated.
Contrast ultrasound is perhaps the most promising
modality for site-specific drug delivery. Microbubbles
are able to carry drugs and genes that cannot otherwise
be administrated (lipophilic drugs, proteins, silencing
RNAs, DNA, etc.).114 The application of a high acoustic
pressure (within the limits of standard ultrasound
equipment) can be used to destroy the microbubbles and
release the drugs at the desired location.115 Microbub-
bles have been used effectively as an in vivo drug and
gene delivery system in studies of small animal
models.114,116,117 However, studies in large animals and
humans are lacking.
Besides the transportation of drugs, microbubbles
have been shown to increase the local uptake of drugs.
The exact mechanism that leads to this increased drug
uptake is unknown, but several mechanisms have been
investigated. The main mechanisms proposed are sono-
poration and the induction of endocytosis. Sonoporation
is the creation of transient micropores in the cellular
membrane due to the oscillation and implosion of
microbubbles in an ultrasound beam, thus increasing
cellular membrane permeability.118 Increased uptake by
ultrasound contrast-medicated sonoporation and endo-
cytosis has been demonstrated in vitro.119-121
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CLINICAL APPLICATION
Inflammation and angiogenesis play a central role in
the pathophysiology of atherosclerosis.10,11,15,16,25,26
Moreover, atherosclerotic plaques with extensive
inflammation and/or intraplaque vasa vasorum are
probably at an increased risk of plaque rupture.4 Early
detection of a vulnerable atherosclerotic plaque may
help to identify patients at an increased risk for myo-
cardial infarction or stroke, who may benefit from early
pharmacological intervention. Molecular imaging of
inflammation and angiogenesis can be used to identify
early atherosclerotic lesions in animals before anatomi-
cal wall abnormalities are visible, thus possibly allowing
for early preventive interventions.66,77 In more advanced
atherosclerotic disease, molecular imaging may distin-
guish between culprit and nonculprit lesions, potentially
identifying patients at increased risk of developing
symptomatic disease.56,61,68
Due to the tortuous and ever moving nature of the
coronary arteries, imaging of coronary atherosclerotic
plaques is a major challenge. The use of catheter-based
intravascular imaging techniques has been shown to
accurately visualize coronary atherosclerotic plaques.
Intravascular ultrasound and optical coherence tomog-
raphy are currently available in clinical practice and
novel catheter-based imaging techniques such as intra-
vascular MRI, thermography, and spectroscopy are in
various stages of development.37 Noninvasive evaluation
of coronary atherosclerotic plaques is more challenging.
CT is frequently used to evaluate the coronary anatomy,
but noninvasive molecular evaluation of the coronary
arteries using CT has not yet been investigated. Because
atherosclerosis is a systemic inflammatory disease and
local changes in macrophage content and vasa vasorum
density are often uniformly present in different vascular
beds,34 the presence and composition of atherosclerotic
plaques in the peripheral arteries can be used as an
indication for atherosclerotic disease of the coronary
arteries. This concept was investigated in a recent pro-
spective follow-up study by Hellings et al,122 who
showed that local histological composition of athero-
sclerotic plaques in the carotid arteries was an
independent predictor of future cardiovascular events.
The predictive value of molecular imaging of athero-
sclerotic plaques in the peripheral arteries as a marker for
coronary artery disease has not yet been determined.
Current technical limitations of the individual
imaging techniques might be overcome by multimo-
dality imaging. Multimodality imaging combines
different imaging modalities, using the advantages of
each individual technique to improve the overall accu-
racy. For example, in current clinical practice PET is
almost always used with co-registration of CT. This
allows for the combination of the highly accurate and
quantifiable assessment of biological activity by PET
and the high resolution anatomical information provided
by CT (Figure 2).61,123,124
The identification of suitable target-ligand combi-
nations is a complex process. Molecular imaging requires
the identification of a disease-specific target with high
expression and a targeting ligand with favorable binding
kinetics to the target: the contrast agent should bind to the
target in quantities great enough to overwhelm the signal
from nonspecifically retained contrast. Additionally, the
imaging system should have sufficient sensitivity to
detect the targeted agents present at the site of pathol-
ogy.125 Most of the contrast agents and targets discussed
in the present review have already shown their value in
vivo in animal models of atherosclerosis. However, the
translation of molecular imaging techniques to the human
setting is still limited, making their application and
accuracy in humans uncertain. Before the introduction of
these molecular imaging techniques into the clinical
setting, the safety of the diagnostic contrast agents has to
be confirmed, adhering to the same stringent safety cri-
teria as used for therapeutic drugs. The current experience
with the pharmacokinetics and toxicity of the contrast
agents is limited and mainly based on nontargeted con-
trast agents. The effect of the ligands bound to the
different contrast agents must be studied before studies
can be performed in patients. Most of the studies did not
evaluate the effects of variable dosing, repeated mea-
surements, and routes of disposal.
The use of molecular imaging has led to substantial
advances in oncologic drug development. In different
stages of drug development, from target validation to
phase 3 trials, molecular imaging-derived measurements
have been used as a surrogate endpoint and thus have
facilitated drug development and implementation.126
The availability of accurate surrogate endpoints will
benefit the development of new cardiovascular drugs as
well.3 Molecular imaging may provide more insight into
the pathophysiological mechanisms of atherosclerosis,
aiding in target identification and validation in vivo.
Furthermore, the use of molecular imaging may reduce
the follow-up time needed in clinical trials, improve
drug substance selection, and monitor treatment effects
during pharmacological trials. A number of studies have
shown that the evaluation of anti-inflammatory treat-
ment effects of lipid lowering treatment by molecular
imaging of atherosclerosis is feasible.55,62,77
CONCLUSION
Molecular imaging of intraplaque vasa vasorum is
feasible and effective in ex vivo experiments and in vivo
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animal models by the detection of inflammation and
angiogenesis. The introduction of molecular imaging
techniques in clinical practice will increase the under-
standing of the role of inflammation and angiogenesis by
elucidating their temporal relation in the disease process.
The ability of molecular imaging to detect subclinical
atherosclerotic disease and to identify vulnerable
plaques may cause a revolution in the management of
patients with atherosclerosis.
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